Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list

Novo's new insulin Awiqli and obesity prospect CagriSema are each expected to rake in billions by 2030, according to Clarivate Analytics’ Drugs to Watch in 2025 report. Lilly's Ebglyss is also in line for a major haul.